3 Passive Income Secrets for Dividend Investors
You'll make a lot more money if you know how to find and keep dividend payers in your portfolio.
Abbott Laboratories(ABT)
New York Stock Exchange
ABT
$110.22
$1.57
1.4%
Price as of July 1, 2022, 4:00 p.m. ET
View Interactive ABT Charts
Principal business is the discovery, development, manufacture and sale of a broad and diversified line of health care products. Company has four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
Interactive Chart
Compare ABT Stock to Peers
| Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
$110.22 | $193B | -5.2% | 146.0% |
|
ISRG |
$206.10 | $74B | -34.1% | 101.3% |
|
TDOC |
$34.83 | $6B | -78.8% | 1.7% |
|
NVCR |
$73.30 | $8B | -60.2% | 314.1% |
|
UNH |
$517.40 | $485B | 28.1% | 198.5% |
News & Analysis: Abbott Laboratories
The Fool has written over 1000 articles on Abbott Laboratories.
2 Dividend Stocks for a Lifetime of Passive Income
These reliable businesses have delivered steadily growing profits to shareholders for decades, and they could keep it going indefinitely.
5 Dividend Kings to Buy Now
These stocks have each raised their payouts to shareholders for at least half of a century.
Why Investors Should Focus on Abbott's Medical Devices
Advances in the core business highlight stable growth prospects.
Finally, a Reasonable Price For This Healthcare Blue Chip
Abbott Laboratories is a blue chip worth scooping up when it goes on sale.
2 Top Healthcare Stocks Near 52-Week Lows to Buy
These two businesses are stronger than ever, but their stock prices are at their lowest points in at least a year.
3 Dividend Stocks to Double Up on Right Now
They're profitable, growing, hiking their payouts, and surviving the bear market without breaking a sweat.
Stock Market Drop: 3 Cheap Healthcare Stocks to Buy Right Now
Declines in the market make now the time to go bargain hunting.
Is Abbott Laboratories Stock a Buy Now?
Abbott generated strong growth in Q1 despite a significant drop in nutritional revenue.
What Could the Baby Formula Shortage Mean for Abbott Laboratories?
There are more stormy waters ahead, but they might not be a problem in the end.
